Loading patent…
AssigneeAkston Biosciences Corporation
InventorsTodd C. ZION, Thomas M. LANCASTER
Estimating the term…
The present disclosure relates to fusion proteins, e.g., insulin-Fc fusion proteins, compositions thereof, and their use to treat cancer cells and cancer tumors in subjects in need thereof. The fusion protein exhibits an anti-tumor effect on a cancer cell in the subject after administration, such as downregulation of insulin receptor, downregulation of insulin-like growth factor 1 receptor (IGF1R), decreased phosphorylated Akt, and a combination thereof. The disclosure relates to methods of downregulating insulin-like growth factor 1 receptor (IGF1R) in a subject in need thereof, as well as methods of inhibiting cancer cell metabolism, growth, and/or proliferation.
A fusion protein comprising an insulin polypeptide and an Fc fragment, wherein the fusion protein comprises the sequence:
A fusion protein comprising an insulin polypeptide and an Fc fragment, wherein the fusion protein comprises the sequence:
A fusion protein comprising an insulin polypeptide, a linker, and an Fc fragment, wherein the insulin polypeptide comprises the sequence:
(canceled)
-17. (canceled)
-33. (canceled)
Dependencies are inferred from the claim text.